Physician profile
Christopher Hisel
NPI 1396760419
$12,413.12
in general payments reported to CMS, 2019-2025
50 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $1,604 · 2021: $2,045 · 2022: $1,921 · 2023: $1,939 · 2024: $1,871 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,717.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,723.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,547.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,334.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $892.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $882.72 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $609.97 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $548.54 | 2020-2025 | |
| Pfizer INC. | $524.20 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $506.28 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Amgen INC. | $352.90 | 2019-2025 | Repatha, Otezla, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $262.68 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $253.28 | 2024-2025 | Zenpep, Vowst |
| Allergan, INC. | $209.93 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $195.40 | 2022-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.53 | 2019-2023 | Synjardy |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.